

1 A comparative study of real-time RT-PCR based SARS-CoV-2
2 detection methods and its application to human derived and
3 surface swabbed material

4 Aizhan Tastanova^{1, ¶}, Corinne Isabelle Stoffel^{1, ¶}, Andreas Dzung^{1, ¶}, Phil Fang Cheng^{1, ¶}, Elisa
5 Bellini¹, Pål Johansen¹, Agathe Duda¹, Stephan Nobbe¹, Reto Lienhard², Philipp Peter
6 Bosshard^{1, ¶}, Mitchell Paul Levesque^{1, *}

7

8 ¹ - Department of Dermatology, University Hospital Zurich and Medical Faculty, University of Zurich,
9 Zurich, Switzerland

10 ² - ADMed Microbiologie, 2300 La Chaux-de-Fonds, Switzerland

11 [¶] - These authors contributed equally

12 ^{*} – Lead author

13

14 Running Head: A comparative study of real-time RT-PCR based SARS-CoV-2 detection methods

15

16 Correspondence to: Mitchell Paul Levesque, Mitchell.Levesque@usz.ch

17 University of Zurich, University Hospital Zurich, Department of Dermatology, Wagistrasse 14, CH-
18 8952, Schlieren, Zürich, Switzerland

19

20

21 **Abstract**

22 Real-time reverse transcription polymerase chain reaction (RT-PCR) remains a gold standard in
23 detection of various viral diseases. In the COVID-19 pandemic, multiple RT-PCR based tests were
24 developed to screen for viral infection. As an emergency response to growing testing demand, we
25 established a SARS-CoV-2 PCR diagnostics platform for which we compared different commercial
26 and in-house RT-PCR protocols. We evaluated four commercial (CDC 2019-nCoV, Applied
27 Biosystems™ 2019-nCoV Assay Kit v1 TF-SinglePlex, 2019-nCoV Assay Kit v2 TF-MultiPlex, and
28 EURORealTime SARS-CoV-2), one customized (Institute Pasteur), and one in-house RT-PCR
29 protocols with 92 SARS-CoV-2 positive and 92 SARS-CoV-2 negative samples. Furthermore, we
30 compared economical and practical characteristics of these protocols. We also developed a highly
31 sensitive digital droplet PCR (ddPCR) method. Finally, we conducted a local environmental study for
32 the presence and infectivity of SARS-CoV-2 on different surfaces in a quarantined household using
33 RT- and ddPCR methods. We found very low limits of detection (1 or 2 viral copies/μL), high
34 sensitivities (93.6-97.8%) and specificities (98.7-100%) for the tested RT-PCR protocols. We further
35 demonstrated the feasibility of downscaling two of the commercial protocols, which could optimize
36 testing capacity. In the local environmental study, only one surface sample tested positive for viral
37 RNA, but without detectable infectivity in vitro. Tested commercial and customized RT-PCR detection
38 kits show very good and comparable sensitivity, and specificity, and the kits could be further
39 optimized for use on SARS-CoV-2 viral samples derived from human and surface swabbed samples.

40

41

42 Introduction

43

44 On March 11, 2020, the World Health Organization (WHO) declared a pandemic due to the quick
45 spread of a respiratory disease caused by the novel Severe Acute Respiratory Syndrome Coronavirus
46 2 (SARS-CoV-2). With positive cases growing in multiple countries and due to its high transmissibility,
47 eradicating SARS-CoV-2 is rather unrealistic in the short term (1). In Switzerland, the second wave of
48 the SARS-CoV-2 is predicted to be slower than the first one, but with a higher case fatality rate (2).
49 The same situation was reported for the Spanish Flu by the WHO, where the 2nd and 3rd waves of
50 the infection claimed more lives and the pandemic lasted for almost 2 years and resulted in at least 50
51 million deaths Worldwide (3). Another important factor contributing to the rapid spread of COVID-19
52 pandemic is an unusually high number of asymptomatic spreaders (4, 5). Therefore, continuous
53 testing and reliable detection of the virus is an essential part of controlling the spread of SARS-CoV-2
54 (6).

55 In March 2020, we initiated an in-house platform for SARS-CoV-2 diagnostics in a routine
56 microbiology lab as part of an emergency response to a growing demand for test capacity. Currently,
57 the gold standard for the detection and diagnosis of SARS-CoV-2 infection is based on the real-time
58 reverse transcription PCR (RT-PCR). Our overall goal was to provide in-house SARS-CoV-2
59 diagnosis to all patients and personnel, to ensure the safe and efficient continuation of the health care
60 work within the hospital and the protection of high-risk patients. The aims of this study were: *i*) to
61 evaluate four commercially available, one customized, and one in-house RT-PCR test by comparing
62 the limit of detection (LoD), sensitivity using a panel of SARS-CoV-2 confirmed cases, and specificity
63 using a group of non-COVID respiratory samples; *ii*) to examine the feasibility of down-scaling two
64 commercial protocols in order to optimize the testing capacity; *iii*) to develop a droplet digital PCR
65 (ddPCR) assay to increase test sensitivity and provide more accurate quantitation of viral RNA; and
66 *iv*) to conduct a local environmental study in a quarantined household by using two validated RT-PCR
67 and ddPCR protocols.

68

69

71 [Methods](#)

72 [Clinical samples](#)

73 Patient samples were collected by nasopharyngeal and/or oropharyngeal swabs (iClean, CM-FS913,
74 San Ramon, USA) at the University Hospital Zurich and at ADMed Laboratory in La Chaux-de-Fonds
75 (COPAN, Brescia, Italy) . The non-COVID-19 samples (other respiratory disease samples) were
76 kindly provided by ADMed Laboratory and were selected after having been tested on the Respiratory
77 Panel FilmArray on Biofire (bioMérieux). Household samples were collected by swabbing of the
78 different surfaces in a quarantined household of a SARS-CoV-2 positive patient. All swabs were
79 stored in a viral transport medium (CDC formulation (7) or Eswab (AMIES, COPAN, Murrieta, United
80 States)) at 4 °C for max. 48 hours or stored at -80 °C until further analyses. All household swabbing
81 participants provided informed consent for the study and both the assay establishment and household
82 studies were approved by the Cantonal Ethics Committee: BASEC-Nr-2020-00660 and BASEC-Nr-
83 2020-00659, respectively.

84

85 [RNA extraction](#)

86 Viral RNA was extracted as previously described using magnetic bead-based (SpeedBeads, GE
87 Healthcare, Darmstadt, Germany) extraction kit for KingFisher instrument (MagMax, Thermo Fisher,
88 Waltham, Massachusetts, U.S) (8).

89

90 [Detection of SARS-CoV-2 by Reverse-Transcriptase PCR \(RT-PCR\) protocols](#)

91 Four commercially available, one customized from Pasteur Institute and in-house optimized RT-PCR
92 protocols (description available in S1 Table) were compared. Primer probes design, reaction mix and
93 thermal cycling conditions are shown in S2, S3 and S4 Tables, respectively. All RT-PCR protocols
94 were run according to manufacturer instructions on a QuantStudio 5 real-time PCR-System (Applied
95 Biosystems, Switzerland) and data were analyzed with the Design and Analysis Software DA 2.4
96 (Applied Biosystems) except for the Euroimmun protocol, which was run on LightCycler® 480 II
97 (RocheDiagnostics, Switzerland). Fast cycling mode was used and a comparative Ct analysis method
98 was performed.

99 For the CDC protocol, a RT-PCR result was defined as *inconclusive* if only the N1 gene (plus/minus
100 N3 gene) was positive, or if only the N2 gene (plus/minus N3 gene) was positive. For the TF-
101 MultiPlex, TF-SinglePlex, and Oncobit protocols, a RT-PCR result was considered as *inconclusive* if
102 only one out of 2 or 3 of the viral genes was positive. Inconclusive results were not repeated. The
103 Euroimmun protocol does not have the *inconclusive* category.

104

105 [Detection of SARS-CoV-2 by Droplet Digital PCR \(ddPCR\)](#)

106 The droplet digital PCR (ddPCR) protocol for SARS-CoV-2 detection targets two viral genomic
107 regions of the SARS-CoV-2 gene (ORF1ab and N2) and uses the human RNase P gene as an in-
108 process control. We used the following probes for the three genes: ORF1ab (FAM and HEX), N2
109 (FAM) and RNase P (HEX). Briefly, 20 μ L of reaction mix (containing 1-Step RT-ddPCR Advanced Kit
110 for Probes Mastermix (1864022, Bio-Rad)) was combined with 10 μ L of RNA sample for a final
111 reaction volume of 30 μ L. Final concentration of primers (ORF1ab, N2, RNaseP) was 90 nM, RdRP
112 probes was 19.5 nM, N2 probe was 30 nM and RNase P probe was 40nM. The SARS-CoV-2 Positive
113 Run Control (#COV019CE, Bio-Rad) was used as positive control. DdPCR was run according to the
114 program shown in S5 Table using QX200 Droplet Digital PCR System (Bio-Rad). The swabbing
115 household samples from laptop, newspaper, door handle, as well as the non-template control (NTC)
116 were tested in two independent runs.

117

118 [Limit of detection, sensitivity and specificity calculation](#)

119 Limit of detection (LoD) of four published SARS-CoV-2 detection protocols (CDC, TF-MultiPlex, TF-
120 SinglePlex, and Euroimmun) was determined by using a dilution of an external quality assessment
121 (EQA) quantitative test sample (9) Linear regression was used to determine the line of best fit for
122 relationship between Ct and viral copies. A Ct value of 40 was set to be the minimum amount of viral
123 copies detected by RT-PCR. LoD for Oncobit ddPCR protocol was determined by using a dilution of
124 the SARS-CoV-2 Positive Run Control (#COV019CE, Bio-Rad).

125 For sensitivity and specificity value calculations of each assay, the results of RT-PCR obtained from
126 the ADMed Laboratory (La Chaux-de-Fonds) were used as gold standard reference. The sensitivity

127 was defined with the following formula “ $TP/(TP+FN)$ ”, while specificity was defined as
128 “ $TN/(TP+FP)$ ” where: TP is true positive, FP is false positive, TN is true negative, and FN is false
129 negative. If the result of tested assays matched the reference, it was labeled concordant. If the result
130 from the tested assays did not match the gold reference, it was labeled discordant. Inconclusive
131 results were excluded from sensitivity and specificity calculations.

132

133 [SARS-CoV-2 infectivity assay](#)

134 The viral infectivity assay was performed as previously described (10-12) with slight modifications.
135 Briefly, 5×10^4 Vero E6 cells (ATCC #CCL-81) were seeded on 96-well flat bottom cell culture plates in
136 200 μ L of high glucose DMEM medium supplemented with L-Glutamate, sodium pyruvate, non-
137 essential amino acids, HEPES, 5% fetal cow serum (FCS), and Normocin™ (Cat. No. ant-nr-1,
138 InvivoGen, Toulouse France). After 24 hours incubation (37 °C, 5% CO₂), the medium was removed
139 and 100 μ L virus test solution or the positive SARS-CoV-2 control (kindly provided by Prof. Volker
140 Thiel, Inst. Virology & Immunology, University of Berne) was added in 2-fold serial dilutions to the
141 cells. The plates were incubated for 48 hours at 37 °C. The cells were then fixed with 10%
142 formaldehyde solution for 15 minutes at room temperature, rinsed with phosphate buffered saline
143 (PBS), and stained with 1% crystal violet stain solution (Pan Reac AppliChem Cat. No. 252532.1211,
144 Darmstadt, Germany) for 15 minutes at room temperature. The staining solution was removed, the
145 cells were rinsed twice with PBS, and the plates dried at room temperature before assessment for
146 viral plaques.

147

148

149

150 Results

151 Description and comparison of SARS-CoV-2 RT-PCR detection protocols

152 The six RT-PCR protocols compared in this study utilize the same principle of isolating viral RNA from
153 the nasopharyngeal and/or oropharyngeal swabs or bronchial fluid and running a 1-step reverse
154 transcription reaction followed by real time amplification of two or three SARS-CoV-2 target genes
155 (Figure 1A). We summarized and compared all tested RT-PCR protocols in Figure 1B. All protocols
156 have internal (IC), non-template (NTC) and positive controls (PC). In TF-MultiPlex, the phage MS2 is
157 added as IC that serves as both RNA isolation and reaction control. All other protocols except for
158 Euroimmun (where type of IC is not indicated) use a widely accepted reaction control RNaseP to
159 ensure that RNA isolation worked and RT-PCR reaction was not inhibited. Protocol's design are either
160 singleplex, doubleplex or multiplex. Euroimmun protocol stands out with its design, with two target
161 probes coupled to the same reporter color FAM. The viral RNA input is 5 μ L to 10 μ L.

162 Due to unspecific E-gene amplification (S6 Table), the protocol developed by Pasteur institute in Paris
163 was not used further in this comparative study.

164

165 Limit of detection of real-time RT-PCR and ddPCR SARS-CoV-2 detection protocols

166 With a Ct-value cut-off of 40, the five RT-PCR SARS-CoV-2 detection protocols (CDC, TF-MultiPlex,
167 TF-SinglePlex, Euroimmun, Oncobit) as well as Oncobit ddPCR protocol showed limit of detection
168 (LoD) between 1 and 2 viral copies/ μ L (Figure 2A, B). Values below 1 copy/ μ L indicate high sensitivity
169 of the tested protocol (Figure 2A, B).

170

171 Specificity & Sensitivity of real-time RT-PCR SARS-CoV-2 detection protocols

172 For the sensitivity and specificity of the SARS-CoV-2 detection protocols (CDC, TF-SinglePlex, TF-
173 MultiPlex, Euroimmun, Oncobit) we used a cohort of 92 SARS-CoV-2 positive samples and 92 SARS-
174 CoV-2 negative samples that were kindly provided by ADMed Laboratory. A comparison to SARS-
175 CoV-2 positive results showed similar sensitivity of all tested protocols with 93.6% for TF-SinglePlex
176 and 96.7-97.8% for the other protocols (Figure 3A). In the specificity cohort, 22 samples had

177 confirmed diagnosis of other respiratory diseases (S7 Table) and 70 samples tested negative for all
178 listed respiratory diseases including SARS-CoV-2. All protocols, except TF-SinglePlex, showed no
179 cross reactivity (Figure 3A) including samples that were positive for four other types of corona viruses
180 (S7 Table). The specificity was thus 100% for all protocols except for TF-SinglePlex, which had a
181 specificity of 98.7% (Figure 3A).

182 Inconclusive results were found in 0.5-3.2% of these 184 samples, with TF-MultiPlex and Oncobit
183 providing the most accuracy (Figure 3A). Comparing RT-PCR results (positive, negative, inconclusive)
184 of all 184 samples, we determined the overall non-concordance between all the protocols to be 14.7%
185 (Figure 3B).

186

187 [Optimization of testing capacity](#)

188 To optimize testing capacity, (i) we downscaled recommended reaction volumes in commercial
189 protocols and (ii) we customized published primer/probe sequences to have an in house developed
190 protocol (Oncobit). Using a previously confirmed SARS-CoV-2 positive cohort of 14 samples, we
191 compared CDC and TF-MultiPlex protocols with recommended reaction volume and with reaction
192 volumes reduced by 50%. RNA sample input was always the same. The Oncobit protocol was the
193 cheapest (Figure 1B), had the shortest RT-PCR reaction time requirement (Figure 1B) and had most
194 reliable access to consumables (Microsynth). The specificity and sensitivity of the Oncobit protocol
195 was comparable to other commercial SARS-CoV-2 RT-PCR detection kits (Figure 3A,B).

196 A downscaled CDC protocol showed two (14.3%) *inconclusive* results, a standard TF-MultiPlex
197 protocol showed one (7.1%) false negative result, and a downscaled TF-MultiPlex protocol revealed
198 one (7.1%) false negative as well as one (7.1%) *inconclusive* result (Figure 4A). Furthermore, LoD of
199 downscaled CDC and TF-MultiPlex protocols showed a sensitivity of 1 copy/ μ L with a Ct-value cut-off
200 of 40 (Figure 4B).

201

202 [Environmental study of household of a SARS-CoV-2 positive patient](#)

203 Having compared and established the RT-PCR protocols for SARS-CoV-2 diagnostics, we conducted
204 a local environmental study of the presence and infectivity of SARS-CoV-2 on different surfaces in a
205 household of a SARS-CoV-2 positive patient.

206 On 4th of April 2020, a 42 year old female (P1, mother) patient was the first person to test positive in a
207 family of four (Fig. 5A; Ct values at the time of diagnosis are missing, as patient was tested in a
208 different laboratory). On 7th of April 2020, the patient suffered from shortness of breath, a
209 manifestation that lasted for three days. On the 7th of April 2020, the 42 year old male (father, P2)
210 patient (Figure 5A) tested positive for SARS-CoV-2, symptoms resolving after 10 days. As the
211 symptoms gradually resolved, we observed rising Ct-values in both patients (Figure 5A). On the 12th
212 of April, the two children (6 years old male (P3), 4 year old male (P4)) also tested positive for SARS-
213 CoV-2, but remained asymptomatic at all times (Figure 5A).

214 On the day of household swabbing (25th of April 2020), only the P2 was swabbed again and tested
215 positive, but reported no symptoms. The patient's swab sample as well as surface samples were
216 tested with three different SARS-CoV-2 detection protocols (CDC, TF-MultiPlex, and ddPCR). The
217 laptop keyboard sample tested positive in all three SARS-CoV-2 detection protocols (S8 Table). Two
218 more samples, showed "inconclusive" results in two independent runs with the CDC RT-PCR and in
219 ddPCR tests, viral copies were detected from the same newspaper and a door handle, but remained
220 below the limit of detection (S8 Table). Importantly, no infectivity was observed for the SARS-CoV-2
221 positive patient and the household samples (i.e., laptop keyboard, newspaper, toilet rim) (Figure 5B).

222

223

224

225

226

227

228

229 Discussion

230 Real time RT-PCR remains the most sensitive method for early detection of SARS-CoV-2. Here, we
231 report a comparison of LoD, specificity, sensitivity, economic, and practical advantages of four
232 commercial SARS-CoV-2 detection kits as well as one optimized in house RT-PCR SARS-CoV-2
233 protocol.

234 In this study, we observed a low LoD and high sensitivity for four commercial SARS-CoV-2 RT-PCR
235 detection protocols by using standard quantitative test samples (9) and a cohort of 92 SARS-CoV-2
236 positive samples, respectively. A study comparing RT-PCR to rapid fluorescence
237 immunochromatographic (FIC) assay based SARS-CoV-2 Nucleocapsid protein (NP) antigen
238 detection method showed that sensitivity of the rapid method was only around 75.6% (13), therefore
239 RT-PCR remains a more sensitive detection method for SARS-CoV-2. Furthermore, we tested and
240 confirmed specificity of those protocols with 92 samples that either had confirmed SARS-CoV-2
241 negative result or were collected in pre-pandemic times from patients presenting with respiratory
242 symptoms (listed in S7 Table).

243 Additionally, we demonstrated that downscaling of two commercial protocols that we chose for the
244 diagnostic routine (CDC and TF-MultiPlex), could be an option to save resources. This is especially
245 important in times when a high demand for SARS-CoV-2 testing causes supply chain problems as
246 occurred at the beginning of the pandemic in Europe. As an alternative strategy to optimize costs and
247 increase testing capacity, we developed an in-house protocol in collaboration with the diagnostics
248 company Oncobit and adapted previously published primer sequences for multiplex analysis. The
249 customized Oncobit potocol was the least costly and fastest protocol when compared to other
250 commercial RT-PCR protocols tested in this study.

251 Finally, we conducted a local environmental study by swabbing surfaces in a quarantined household
252 of a SARS-CoV-2 positive patient. A laptop keyboard sample showed positive results in three RT-
253 PCR detection protocols with Ct values above 30. On the day of household swabbing, the
254 quarantined patient tested positive (cycle thresholds >30) by pharyngeal swabbing with three different
255 protocols, while being asymptomatic for 2 days. We expected that the patient's personal items, such
256 as a toothbrush, should be positive for SARS-CoV-2. However, the dry condition at the time of
257 swabbing could explain the negative result. A laptop keyboard might have a different surface and we

258 assume that a moist environment might preserve the virus for detection, but not enough to support
259 viral infectivity. A possible explanation for the non-infectivity of the samples could be the rather low
260 cycle thresholds of the samples in the RT-PCR analysis, suggesting that the amount of virus might
261 have been too low for viral isolation. Furthermore, swabbing of the households of symptomatic or pre-
262 symptomatic SARS-CoV-2 positive individuals would be of interest to test. Further studies are needed
263 to investigate different swabbing conditions (wet/dry) and what is the impact of freeze-thawing cycles
264 as well as storage in viral transport medium on the detection and infectivity of a SARS-CoV-2 virus.
265 Interestingly, the result of a quarantined household in Zurich is in line with the study of Döhla et al. in
266 Germany where 21 households of SARS-CoV-2 positive patients were swabbed and only 3.36%
267 (7.6% in our study) of object samples collected from household surfaces tested positive, but non-
268 infective (14). Two other European studies (14, 15) and our study support the hypothesis that indirect
269 environmental transmission may only play a minor role, which needs clarification in further studies.

270 Summarizing the comparative study, we demonstrated that most commercial and customized RT-
271 PCR based detection protocols are highly effective at detecting viral presence in classical
272 nasopharyngeal and/or oropharyngeal swabs and due to its high sensitivity can be applied to testing
273 of environmental samples.

274

275

276

277

278

279

280

281

282 Acknowledgements

283 We thank Gaetana Restivo for help with obtaining ethical clearance for the study. We are very grateful
284 to Jan Kaesler, Mirka Schmid, Muriel Traexler, Melanie Maudrich and the whole Dermatology biobank
285 team of USZ for big help with running the experiments and technical help.

286

287 Author Contribution

288 The idea of the study: MPL, PPB, AT, CIS, Adz, PFC.. Experimental design: MPL, PPB, AT, CIS, EB,
289 ADz, PJ. Experiment execution: AT, CIS, EB, ADz, PJ, AD. Data analysis: CIS, PFC, AT, ADz, EB,
290 PJ. Manuscript draft: AT, CIS. All authors edited and contributed into manuscript writing.

291

292 Funding

293 This research was supported by grants received by MPL from the University Hospital Zurich.

294

295 Conflict of interest

296 MPL is a founder and shareholder of Oncobit, which partially funded the establishment of the novel
297 real-time RT-PCR and ddPCR assays.

298

299

300 References

- 301 1. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, Storgaard M, Al Khalili
302 S, Simonsen L. 2020. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
303 Lancet Infect Dis 20:e238-e244.
- 304 2. Balabdaoui F, Mohr D. 2020. Age-stratified model of the COVID-19 epidemic to analyze the
305 impact of relaxing lockdown measures: nowcasting and forecasting for Switzerland. medRxiv
306 doi:10.1101/2020.05.08.20095059:2020.05.08.20095059.
- 307 3. World Health Organization. 2018. 1918 Pandemic Influenza: Three Waves.
308 <https://www.cdc.gov/flu/pandemic-resources/1918-commemoration/three-waves.htm>.
309 Accessed September 7.
- 310 4. Bi J, Lin Y, Zhong R, Jiang G, Verma V, Shi H, Li J, Tong X, Li Y, Hu D, Liang W, Han G, He
311 J. 2020. Prevalence and clinical characterization of cancer patients with asymptomatic SARS-
312 CoV-2 infection history. J Infect doi:10.1016/j.jinf.2020.07.018.
- 313 5. Oran DP, Topol EJ. 2020. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative
314 Review. Ann Intern Med 173:362-367.
- 315 6. World Health Organization. 2020. Coronavirus disease (COVID-19) pandemic: Strategy and
316 planning. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/strategies-and-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/strategies-and-plans)
317 [plans](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/strategies-and-plans). Accessed September 7.
- 318 7. Centers for Disease Control and Prevention. 2020. PREPARATION OF VIRAL TRANSPORT
319 MEDIUM. [https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-](https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf)
320 [Medium.pdf](https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf). Accessed March 20.
- 321 8. Eichhoff OM, Bellini E, Lienhard R, Stark WJ, Bechtold P, Grass RN, Bosshard PP, Levesque
322 MP. 2020. Comparison of RNA extraction methods for the detection of SARS-CoV-2 by RT-
323 PCR. medRxiv doi:10.1101/2020.08.13.20172494:2020.08.13.20172494.
- 324 9. Instand. 2020. Novel coronavirus SARS-CoV-2 (2019-nCoV) - preponed INSTAND EQA
325 scheme - virus genome detection coronaviruses. [https://www.instand-](https://www.instand-ev.de/en/news/detail/news/neuartiges-coronavirus-sars-cov-2-2019-ncov-im-vorgezogenen-instand-ringversuch-virusgenom-nachw/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=f91865b86af167390788c7f404b16e7e)
326 [ev.de/en/news/detail/news/neuartiges-coronavirus-sars-cov-2-2019-ncov-im-vorgezogenen-](https://www.instand-ev.de/en/news/detail/news/neuartiges-coronavirus-sars-cov-2-2019-ncov-im-vorgezogenen-instand-ringversuch-virusgenom-nachw/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=f91865b86af167390788c7f404b16e7e)
327 [instand-ringversuch-virusgenom-](https://www.instand-ev.de/en/news/detail/news/neuartiges-coronavirus-sars-cov-2-2019-ncov-im-vorgezogenen-instand-ringversuch-virusgenom-nachw/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=f91865b86af167390788c7f404b16e7e)
328 [nachw/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=f](https://www.instand-ev.de/en/news/detail/news/neuartiges-coronavirus-sars-cov-2-2019-ncov-im-vorgezogenen-instand-ringversuch-virusgenom-nachw/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=f91865b86af167390788c7f404b16e7e)
329 [91865b86af167390788c7f404b16e7e](https://www.instand-ev.de/en/news/detail/news/neuartiges-coronavirus-sars-cov-2-2019-ncov-im-vorgezogenen-instand-ringversuch-virusgenom-nachw/?tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=f91865b86af167390788c7f404b16e7e). Accessed 12 November.

- 330 10. Aoki-Utsubo C, Chen M, Hotta H. 2018. Virucidal and Neutralizing Activity Tests for Antiviral
331 Substances and Antibodies. *Bio-protocol* 8:e2855.
- 332 11. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H,
333 Wen Y, Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19
334 recovered patient cohort and their implications. doi:10.1101/2020.03.30.20047365 %J
335 medRxiv:2020.03.30.20047365.
- 336 12. Chu H, Chan JF, Yuen TT, Shuai H, Yuan S, Wang Y, Hu B, Yip CC, Tsang JO, Huang X,
337 Chai Y, Yang D, Hou Y, Chik KK, Zhang X, Fung AY, Tsoi HW, Cai JP, Chan WM, Ip JD, Chu
338 AW, Zhou J, Lung DC, Kok KH, To KK, Tsang OT, Chan KH, Yuen KY. 2020. Comparative
339 tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with
340 implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19:
341 an observational study. *Lancet Microbe* 1:e14-e23.
- 342 13. Diao B, Wen K, Zhang J, Chen J, Han C, Chen Y, Wang S, Deng G, Zhou H, Wu Y. 2020.
343 Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of SARS-CoV-2
344 infection. *Clin Microbiol Infect* doi:10.1016/j.cmi.2020.09.057.
- 345 14. Döhla M, Wilbring G, Schulte B, Kümmerer BM, Diegmann C, Sib E, Richter E, Haag A,
346 Engelhart S, Eis-Hübinger AM, Exner M, Streeck H, Schmithausen RM. 2020. SARS-CoV-2
347 in environmental samples of quarantined households. medRxiv
348 doi:10.1101/2020.05.28.20114041:2020.05.28.20114041.
- 349 15. Fernandez-de-Mera IG, Rodriguez Del-Rio FJ, de la Fuente J, Perez-Sancho M, Hervas D,
350 Moreno I, Dominguez M, Dominguez L, Gortazar C. 2020. Detection of environmental SARS-
351 CoV-2 RNA in a high prevalence setting in Spain. *Transbound Emerg Dis*
352 doi:10.1111/tbed.13817.
- 353 16. Pasteur Institute. 2020. Protocol: Real-time RT-PCR assays for the detection of SARS-CoV-
354 2, Institut Pasteur, Paris. [https://www.who.int/docs/default-source/coronaviruse/real-time-rt-
355 pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf](https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf). Accessed
- 356 17. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S,
357 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
358 Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,

359 Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-
360 time RT-PCR. Euro Surveill 25.

361 18. Centers for disease control and prevention. 2020. Research Use Only 2019-Novel
362 Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes.

363 <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>. Accessed
364 September 7.

365 19. Dong L, Zhou J, Niu C, Wang Q, Pan Y, Sheng S, Wang X, Zhang Y, Yang J, Liu M, Zhao Y,
366 Zhang X, Zhu T, Peng T, Xie J, Gao Y, Wang D, Zhao Y, Dai X, Fang X. 2020. Highly
367 accurate and sensitive diagnostic detection of SARS-CoV-2 by digital PCR. medRxiv
368 doi:10.1101/2020.03.14.20036129:2020.03.14.20036129.

369

370 Figure legends

371 **Figure 1: Summary of different SARS-CoV-2 real-time RT-PCR detection protocols**

372 **A.** SARS-CoV-2 genome structure and coverage by different protocols, continuous line indicate
373 relative gene coverage by the detection protocol. **B.** Comparative overview of six different RT-PCR
374 protocols.

375 *Abbreviations: CDC SARS-CoV-2 (Centers for disease control and prevention SARS-CoV-2); TF-*
376 *SinglePlex (Applied BiosystemsTM TaqManTM 2019-nCoV Assay Kit v1), TF-MultiPlex (Applied*
377 *BiosystemsTM Multiplex TaqMan 2019-nCoV Assay Kit v2 RESEARCH USE ONLY (R.U.O.) kit);*
378 *Euroimmun (EUORealTime SARS-CoV-2 (For research use only (RUO)) (Cat. No. MP 2606-*
379 *0425)); Pasteur Paris Protocol (WHO) (Real-time RT-PCR assays for the detection of SARS-CoV-2,*
380 *Institute Pasteur (Paris)); Oncobit real-time RT-PCR (in-house customized RT-PCR protocol).*

381

382 **Figure 2: Limit of detection (LoD) of real-time RT-PCR and ddPCR SARS-CoV-2 detection** 383 **protocols**

384 **A.** Limit of detection (viral copies/ μ L) of different target genes of CDC, TF-SinglePlex, TF-MultiPlex,
385 Euroimmun, Oncobit RT-PCR and Oncobit ddPCR SARS-CoV-2 detection protocols. **B.** Calculated R^2
386 values of SARS-CoV-2 detection protocols.

387

388 **Figure 3: Specificity & Sensitivity of real-time RT-PCR SARS-CoV-2 detection protocols**

389 **A.** Performance calculation (Sensitivity/Specificity) as well as calculation of percentage of
390 inconclusive results of five real-time RT-PCR detection protocols (CDC, TF-SinglePlex, TF-MultiPlex,
391 Euroimmun and Oncobit). Euroimmun RT-PCR detection protocol does not have the *inconclusive*
392 category, *inconclusive* for Euroimmun equals *invalid* result. **B.** Heat-Map summarizing concordance of
393 five real-time RT-PCR detection protocols (CDC, TF-SinglePlex, TF-MultiPlex, Euroimmun and
394 Oncobit) for both sensitivity (bottom) and specificity (top) sample cohorts.

395

396 **Figure 4: Downscaling of the CDC and TF-MultiPlex protocols**

397 **A.** Heatmap summarizing results of standard and downscaled protocol (CDC, TF-MultiPlex); PC –
398 positive control; NTC – Non-template control. For CDC protocol a RT-PCR result was defined as
399 *inconclusive* if either RT-PCR was only positive for N1 (plus/minus N3) or only for N2 (plus/minus N3).
400 For TF-MultiPlex a RT-PCR result was considered as *inconclusive* if only one of the viral genes was
401 positive. **B.** Limit of detection (copies/ μ L) and R^2 values of downscaled protocols (CDC, TF-MultiPlex).
402

403 **Figure 5: Environmental study of SARS-CoV-2 positive patient's household.**

404 **A.** The patient's Ct values and symptom progression. Mean of Ct values of N1, N2 and N3 viral genes
405 are shown (CDC protocol). *P1*: 42 years old female, *P2*: 42 years old male, *P3*: 6 years old male, *P4*:
406 4 years old male patient. Household of the family was swabbed on the 25 of April with patients being
407 asymptomatic for at least 2 days. **B.** An infectivity assay using Vero E6 cells showed no plaque
408 formation for any of the samples that tested positive by real-time RT-PCR (patient's throat, laptop
409 keyboard, newspaper and toilet rim).

410

411

412

413

414

415 **Supplementary tables**

416 S1 Table: Description of real-time RT-PCR assays compared in the study.

RT-PCR protocol	Abbreviated name	RT-PCR Kit/ Primer and probes	Mastermix used in this study	Positive control
CDC 2019- Novel Coronavirus Real-Time RT-PCR Diagnostic Panel (for in-vitro diagnostic	CDC	2019-nCoV EUA-01 Diagnostic Panel Box, Cat. No. 10006606, IDT	TaMan™, Fast Virus 1-step Maste Mix, 4444436, 10mL, Applied biosystems by Thermo Fisher	2019-nCoV_N_Positive Control, Cat. No. 10006625, IDT
Applied Biosystems™ TaqMan™ 2019-nCoV Assay Kit v1	TF-SinglePlex	TaqMan™ 2019-nCoV Assay Kit v1, Cat. No. A47532, Applied biosystems by Thermo Fisher	TaMan™, Fast Virus 1-step Maste Mix, Cat. No. 4444436, 10mL, Applied biosystems by Thermo Fisher	2019-nCoV Control v1, Cat. No. A47533, Applied biosystems by Thermo Fisher
Applied Biosystems™ Multiplex TaqMan 2019-nCoV Assay Kit v2 research use only (R.U.O.) kit	TF-MultiPlex	TaqPath™ COVID-19 Combo Kit, Cat. No. A47813/A47814, Applied biosystems by	TaqPath™ 1-Step Multiplex Master Mix (No ROX™) (4X), Cat. No. A28523, Applied	Positive Control (TaqPath™ COVID-19 Control Kit) Cat. No. A47816), Applied biosystems by

		Thermo Fisher	biosystems by Thermo Fisher	Thermo Fisher
EUORealTime SARS-CoV-2 (For research use only (RUO))	Euroimmun	Cat. No MP 2606-0425	Provided with the kit	Provided with the kit
Real-time RT- PCR assays for the detection of SARS-CoV-2 Institute Pasteur, Paris	Pasteur Protocol Pairs (WHO)	(16, 17) Ordered from Microsynth	Invitrogen Superscript™ III Platinum® One-Step qRT- PCR system Cat. No. 11732-088	Available upon request from Pasteur Institute
In-house customized RT- PCR protocol	Oncobit	(18, 19) Ordered from Microsynth	TaqPath™ 1- Step Multiplex Master Mix (no ROX) (A28521, ThermoFisher)	SARS-CoV-2 Positive Run Control (#COV019CE) of Bio-Rad

417

418

419

420 S2 Table: Oligonucleotide sequences of primers and probes of Oncobit real-time RT-PCR and ddPCR
421 protocols

Primer/probe name	Sequence (5'-3')
N2 forward primer	TTACAAACATTGGCCGCAA
N2 reverse primer	GCGCGACATTCCGAAGAA
N2 probe (<i>FAM</i>)	ACAATTTGCCCCCAGCGCTTCA
ORF1ab forward primer	CCCTGTGGGTTTTACTTAA
ORF1ab reverse primer	ACGATTGTGCATCAGCTGA
ORF1ab probe (<i>Cy5</i>)	CCGTCTGCGGTATGTGGAAAGGTTATGG
RNaseP forward primer	AGATTTGGACCTGCGAGCG
RNaseP reverse primer	GAGCGGCTGTCTCCACAAGT
RNaseP probe (<i>HEX</i>)	TTCTGACCTGAAGGCTCTGCGCG

422

423

424

425

426

427

428

429

430

431

432

433 S3 Table: Reaction mix for Oncobit real-time RT-PCR protocol

Reagents	Volume per reaction:
TaqPath™ 1-Step Multiplex Master Mix (no ROX) (A28521, ThermoFisher) 4X	5µL
N2 probe (FAM) (100µM)	0.05µL
ORF1ab probe (Cy5) (100µM)	0.05µL
RNaseP probe (HEX) (100µM)	0.05µL
N2 forward primer (100µM)	0.06µL
N2 reverse primer (100µM)	0.06µL
ORF1ab forward primer (100µM)	0.06µL
ORF1ab reverse primer (100µM)	0.06µL
RNaseP forward primer (100µM)	0.03µL
RNaseP reverse primer (100µM)	0.03µL
Nuclease free H ₂ O	4.55µL
Total	20.0µl

434

435

436

437

438

439

440

441 S4 Table: Thermal cycling conditions for Oncobit real-time RT-PCR protocol

Stage	Step	Temperature	Time
Hold	UNG incubation	25°C	2 minutes
Hold	Reverse Transcription	53°C	10 minutes
Hold	Activation	95°C	2 minutes
Cycling (40 cycles)	Denaturation	95°C	3 seconds
	Anneal/Extension	60°C	30 seconds

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456 S5 Table: Thermal cycling conditions for Oncobit ddPCR protocol

Stage	Temperature	Time
Hold	50°C	60 minutes
Hold	95°C	10 minutes
Cycling (55 cycles)	95°C	30 seconds
	59°C	1 minute
Hold	98°C	10 minutes
Hold	4°C	1 minute

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471 S6 Table: Results (Ct values) from two different experiments for RT-PCR protocol from Pasteur

472 Institute, Paris

Sample	IP2 gene		IP4 gene		E gene		RNase P(VIC)	
NTC	-	-	-	-	39.2	35.1	-	-
PC 10 ⁷ copies	20.8	18.2	19.7	18.9	18.2	18	-	-
PC 10 ⁵ copies	30.4	25.5	28	27.1	29.2	25.7	-	-
melanoma cell line	-	-	-	-	-	35.6	21.1	22.8

473 NTC- nuclease free water, PC – positive control

474

475

476

477

478

479 S7 Table: Overview of samples used in benchmarking experiments

Respiratory disease type	# of samples
RV/EV (rhinovirus - enterovirus)	4
PIV4 (parainfluenza 4)	1
OC43 (coronavirus OC43)	1
ADV (adenovirus)	1
RSV (respiratory syncytial virus)	5
229E (coronavirus 229E)	2
MPV (metapneumovirus)	2
NL63 (coronavirus NL63)	1
INFA (Influenza type A)	3
INFB (Influenza type B)	1
RHI/EV (rhinovirus - enterovirus)	1
Other respiratory diseases, tested negative for all above respiratory pathogens and for COVID-19	70

SARS-CoV-2	106
------------	-----

480

481

482

483

484 S8 Table: Ct values and Copies/reaction of patient's throat and surface samples (CDC, TF-MultiPlex,
485 ddPCR)

Sample	CDC (Ct values)					TF-MultiPlex (Ct values)					ddPCR (Copies/ μ L)				
	N1	N2	N3	RP	Interp.	N	ORF1ab	S	MS2	Interp.	N2	ORF1ab	RP	Accepted droplets	Interp.
Neg. control	-	-	-	-	Neg.	-	-	-	25.8	Neg.	-	-	-	21321.5	Neg.
Throat	35.6	36.5	36.4	28.4	Pos.	29.7	30.1	30.7	26.0	Pos.	7	2.8	1042	16706	Pos.
Smart-phone screen	-	-	-	-	Neg.	-	-	-	25.7	Neg.	-	-	-	25636.5	Neg.
Laptop Keyboard	35.8	37.8	35.2	34.4	Pos.	38.8	-	43.2	26.2	Pos.	3.3	5.2	13.1	19332.5	Pos.
Newspaper	37.2	-	-	35.6	Inconcl.	-	-	-	26.8	Neg.	1.58	-	3.82	27789.5	Neg.
Toilet Rim	-	38.4	36.6	35.2	Inconcl.	-	-	-	26.5	Neg.	-	-	26.8	14076	Neg.
Toilet water	-	-	-	35.2	Neg.	-	-	-	26.1	Neg.	-	-	5.09	13859	Neg.
Razor Blade	-	-	-	35.4	Neg.	-	-	-	26.2	Neg.	-	-	7.68	15327	Neg.
Toothbrush	-	-	-	31.7	Neg.	-	-	-	26.1	Neg.	-	-	97	14831	Neg.
Glasses	-	-	-	35.2	Neg.	-	-	-	26.1	Neg.	-	-	5.09	13859	Neg.
Wheel car	-	-	-	34.7	Neg.	-	-	-	25.9	Neg.	-	-	11.6	10116	Neg.
Pillow	-	-	-	31.4	Neg.	-	-	-	25.8	Neg.	-	-	127	11727	Neg.
Fridge handle	-	-	-	36.1	Neg.	-	-	-	26.2	Neg.	-	-	-	16506	Neg.
Glas	-	-	-	37.4	Neg.	-	-	-	26.3	Neg.	-	-	-	13259	Neg.

(30cm)															
Door handle	-	-	-	36.5	Neg.	-	-	-	26.4	Neg.	-	-	1.7	26614.5	Neg.

486 *Abbreviations: Interp. – Interpretation; Neg. – Negative; Pos. – Positive.*

487


488

489

490

A

medRxiv preprint doi: <https://doi.org/10.1101/2020.11.23.20236257>; this version posted November 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



B

	CDC SARS-CoV-2	TF-SinglePlex	TF-MultiPlex	Euroimmun	Pasteur Paris Protocol (WHO)	Oncobit RT-PCR
Targets (Dyes)	N1 (FAM) N2 (FAM) N3 (FAM) RNAseP (FAM)	ORF1ab (FAM) N (VIC) S (VIC) RNAseP (JUN)	ORF1ab (FAM) N (VIC) S (ABY) MS2 (JUN)	ORF1ab & N (SARS-CoV-2, FAM) IC (VIC)	RdRp_IP2 (FAM) RdRp_IP4 (HEX) E gene (FAM) RNAseP (HEX)	ORF1ab (HEX) N2 (FAM) RNAseP (Cy5)
Targets/rxn wells	4/4	4/3	4/1	3/1	4/2	3/1
Sample volume well (µL)	5	5	5	10	5	10
Total rxn volume/well (µL)	20	25	25	20	30	20
Design	Singleplex	Singleplex	Multiplex	Multiplex	Doubleplex	Multiplex
Costs (in CHF)	11.60	42	16.50	19	8	5
Average reaction time (minutes)	70	60	70	70-75	105	55


Figure 1: Summary of different SARS-CoV-2 real-time RT-PCR detection protocols

A. SARS-CoV-2 genome structure and coverage by different protocols, continuous line indicate relative gene coverage by the detection protocol.

B. Comparative overview of six different RT-PCR protocols.

Abbreviations: CDC SARS-CoV-2 (Centers for disease control and prevention SARS-CoV-2); TF-SinglePlex (Applied Biosystems™ TaqMan™ 2019-nCoV Assay Kit v1), TF-MultiPlex (Applied Biosystems™ Multiplex TaqMan 2019-nCoV Assay Kit v2 RESEARCH USE ONLY (R.U.O.) kit); Euroimmun (EURORealTime SARS-CoV-2 (For research use only (RUO)) (Cat. No. MP 2606-0425)); Pasteur Paris Protocol (WHO) (Real-time RT-PCR assays for the detection of SARS-CoV-2, Institute Pasteur (Paris)); Oncobit real-time RT-PCR (in-house customized RT-PCR protocol).

A



B

	CDC			TF-MultiPlex			TF-SinglePlex			Euroimmun	Oncobit RT-PCR		Oncobit ddPCR	
	N1	N2	N3	N	ORF1ab	S	N	ORF1ab	S	SARS-CoV-2 (ORF1ab, N)	N2	ORF1ab	N2	ORF1ab
LOD (copies/ μ L)	2.1	1.6	0.3	0.1	0.1	0.1	0.2	0.8	0.05	0.8	0.6	1.8	0.2	0.2
R ²	0.9974	0.9976	0.9980	0.9992	0.9994	0.9966	0.9961	0.9913	0.9949	0.9992	0.9956	0.9930	0.9990	0.9988

Figure 2: Limit of detection (LoD) of real-time RT-PCR and ddPCR SARS-CoV-2 detection protocols

A. Limit of detection (viral copies/ μ L) of different target genes of CDC, TF-SinglePlex, TF-MultiPlex, Euroimmun, Oncobit RT-PCR and Oncobit ddPCR SARS-CoV-2 detection protocols. **B.** Calculated R² values of SARS-CoV-2 detection protocols.

A

	Sensitivity (%)	Specificity (%)	Inconclusive (%)
CDC	96.7	1	2.7
TF_SinglePlex	96.7	98.7	3.2
TF_MultiPlex	93.6	98.7	0.5
Euroimmun	97.8	1	-
Oncobit	97.8	1	1.6

medRxiv preprint doi: <https://doi.org/10.1101/2020.11.23.20236257>; this version posted November 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



B

Figure 3: Specificity & Sensitivity of real-time RT-PCR SARS-CoV-2 detection protocols

A. Performance calculation (Sensitivity/Specificity) as well as calculation of percentage of inconclusive results of five real-time RT-PCR detection protocols (CDC, TF-SinglePlex, TF-MultiPlex, Euroimmun and Oncobit). Euroimmun RT-PCR detection protocol does not have the inconclusive category, inconclusive for Euroimmun equals invalid result. **B.** Heat-Map summarizing concordance of five real-time RT-PCR detection protocols (CDC, TF-SinglePlex, TF-MultiPlex, Euroimmun and Oncobit) for both sensitivity (bottom) and specificity (top) sample cohorts.

A



B

	CDC downscaled			TF-MultiPlex downscaled		
	N1	N2	N3	N	ORF1ab	S
LoD (copies/ μ L)	1	1.1	0.6	0.05	0.04	0.03
R²	0.9995	0.9995	0.9797	0.9999	0.9978	0.9765

Figure 4: Downscaling of the CDC and TF-MultiPlex protocols

A. Heatmap summarizing results of standard and downscaled protocol (CDC, TF-MultiPlex); PC – positive control; NTC – Non-template control. For CDC protocol a RT-PCR result was defined as inconclusive if either RT-PCR was only positive for N1 (plus/minus N3) or only for N2 (plus/minus N3). For TF-MultiPlex a RT-PCR result was considered as inconclusive if only one of the viral genes was positive.

B. Limit of detection (copies/ μ L) and R2 values of downscaled protocols (CDC, TF-MultiPlex).





Figure 5: Environmental study of SARS-CoV-2 positive patient's household.

A. The patient's Ct values and symptom progression. Mean of Ct values of N1, N2 and N3 viral genes are shown (CDC protocol). P1: 42 years old female, P2: 42 years old male, P3: 6 years old male, P4: 4 years old male patient. Household of the family was swabbed on the 25 of April with patients being asymptomatic for at least 2 days. **B.** An infectivity assay using Vero E6 cells showed no plaque formation for any of the samples that tested positive by real-time RT-PCR (patient's throat, laptop keyboard, newspaper and toilet rim).